PF-00299804 in Patients With Head and Neck Squamous Cell Carcinoma
Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
Epidermal growth factor receptor (EGFR) is often over-expressed, and have been related to
poor prognosis in patients with HNSCC. EGFR targeting strategies showed clinical anti-tumor
efficacy in patients with HNSCC. PF-00299804 is a second-generation quinazoline-based
irreversible pan-HER inhibitor. In preclinical studies, PF-00299804 has much lower IC50
values than gefitinib in cell lines engineered to express EGFRvIII mutations (1.2 nM versus
2,700 nM) and produces tumor growth inhibition in gefitinib-resistant xenografts. A phase II
trial of PF-00299804 in patients with recurrent or metastatic HNSCC is currently ongoing and
preliminary report in ASCO 2010 showed its anti-tumor activity against HNSCC. The
investigators suggest a phase II trial of pan-HER inhibitor PF-00299804 in patients with
recurrent or metastatic HNSCC previously treated with platinum-based chemotherapy.